Fusarium is a fungal pathogen of immunosuppressed lung transplant patients associated with a high mortality in those with severe and persistent neutropenia. The principle portal of entry for Fusarium species is the airways, and lung involvement almost always occurs among lung transplant patients with disseminated infection. In these patients, the immunoprotective mechanisms of the transplanted lungs are impaired, and they are, therefore, more vulnerable to Fusarium infection. As a result, fusariosis occurs in up to 32% of lung transplant patients. We studied fusariosis in 6 patients following lung transplantation who were treated at Massachusetts General Hospital during an 8-year period and reviewed 3 published cases in the literature. Cases were identified by the microbiology laboratory and through discharge summaries. Patients presented with dyspnea, fever, nonproductive cough, hemoptysis, and headache. Blood tests showed elevated white blood cell counts with granulocytosis and elevated inflammatory markers. Cultures of Fusarium were isolated from bronchoalveolar lavage, blood, and sputum specimens.
INTRODUCTION
L ung transplantation is now a viable and widely accepted treatment of end-stage lung disease. The first lung transplant was carried out in 1963 as a single left lung transplant from a cadaver where the recipient survived just 18 days, eventually succumbing to renal failure and malnutrition. 36, 37 From that time until the early 1980s, the main problems facing lung transplantation were organ rejection and healing of airway anastamoses. Advances during the early 1980s saw the advent of cyclosporine A, a potent immunosuppressive drug, and improved surgical techniques. This led to the first successful heart-lung transplant for idiopathic pulmonary artery hypertension in 1981, single lung transplant for idiopathic pulmonary fibrosis in 1983, and double lung transplant for emphysema in 1986. 21, 96, 119 From January 1, 1988, to September 30, 2009 , 471,304 single lung transplantations have been carried out the United States alone. 120 Some diseases that cause respiratory failure and may ultimately benefit from lung transplantation include suppurative diseases like chronic obstructive airways disease, bronchiectasis, chronic bronchitis, and cystic fibrosis, and nonsuppurative diseases like emphysema, idiopathic pulmonary fibrosis, primary and secondary pulmonary hypertension, alpha-1 antitrypsin disease, Goodpasture disease, sarcoidosis, rheumatoid disease, hemosiderosis, occupational lung disease, and inhalation burns. 83, 117 Lung transplantation is considered when life expectancy is less than 24Y36 months and patients have New York Heart Association (NYHA) class III and IV symptoms. 69 Lung transplantation is often complicated by bacterial and fungal infections. 45 Invasive fungal infections are serious and potentially life-threatening complications of lung transplantation, occurring in 14%Y32% of recipients. 15, 45, 51 Fungal pneumonias are a significant contributor to the 35% of pneumonia deaths in the first year following lung transplantation. 1, 17 In this group of patients the epidemiology of fungal infections has changed with the use of fluconazole prophylaxis; there has been a significant decrease in the incidence of yeast infections, namely Candida species, and an increase in mold infections. 4, 15, 64, 112, 124 Among these mold infections the incidence of invasive Fusarium species infections is rising, now second only to Aspergillus species. 15, 73, 77, 106, 112 The diagnosis of invasive fusariosis currently has a very poor prognosis. 50 Early diagnosis and treatment are essential to improve the chances of survival. Given the magnitude and severity of the problem, surprisingly little is known about the pathogenesis, clinical characteristics, laboratory diagnosis, and management of fusariosis. 15 The main factors contributing to the acquisition of invasive fusarial infections in lung transplant patients are the following: 1) the protective physical barriers to infection in the lungs are compromised during lung transplantation; 2) the protective mucociliary clearance and cough reflexes are reduced due to denervation of the transplanted lung; 3) the transplanted lung is continuously exposed to the open environment and its microorganisms; 4) patients are immunosuppressed with potent pharmacologic agents; and 5) the incidence of infections caused by drug-resistant and aggressive strains of fungi is increasing. 17, 53, 59, 64, 65 Note that Fusarium species can be acquired from the environment by the recipient following transplantation, or alternatively Fusarium species can be present as a pretransplant colonizing organism in the donor lung that can manifest following transplantation, causing clinical disease in the recipient. 17 The main entry site for Fusarium species is the airways via inhalation of airborne conidia, and the lungs are involved in 31%Y41% of all fusariosis cases. 33, 68, 127 In support of this is the development of sinusitis and pneumonia in the absence of fungemia. 75 Lung involvement can also occur following hematongenous spread of the fungus, which almost always occurs in the immunocompromised. 75 To better understand the emerging role of this pathogen in lung transplant patients, we here examine the clinical characteristics of Fusarium infections in this patient population and evaluate possible risk factors, clinical findings, laboratory diagnosis, response to therapy, and outcomes from clinical cases and the literature.
METHODS

Clinical Data Collection
Six cases of Fusarium infection in lung transplant patients were identified in our institution (Massachusetts General Hospital) by the microbiology laboratory and from discharge summaries. The review period was from January 2001 to November 2008 inclusive; over this time, a total of 73 lung transplants were carried out at Massachusetts General Hospital. 120 Data for these cases were obtained from a detailed study of computerized patient medical records. In addition, we reviewed the English-language literature to identity similar cases of fusariosis in lung transplant patients, searching the MEDLINE database (National Library of Medicine, Bethesda, MD) using the key words ''transplant'' and ''Fusarium.'' We did not constrain the search to any specific time period due to the limited number of published case reports.
Identification and Determination of MIC of Fusarium Species
The Fusarium isolate from Patient 6 ( Tables 1 and 2) was obtained and the species was identified by amplifying and sequencing a portion of the translation elongation factor (TEF) 1> coding region as described by O_Donnell et al. 80 The minimum inhibitory concentration (MIC) of the isolate was determined spectrophotometrically using RPMI 1640 media (Mediatech, Inc., Manassas, VA) following the Clinical and Laboratory Standards Institute microbroth dilution method. All antifungal compounds tested were obtained from Sigma-Aldrich (St. Louis, MO), with the exception of caspofungin (Merck, Whitehouse Station, NJ).
RESULTS
Case Series
We identified 6 lung transplant patients with fusariosis (mean age, 42.6 yr; range, 19Y66 yr) ( Table 1 ). The reasons for lung transplant were cystic fibrosis (2 patients), interstitial 
Liposomal amphotericin B, voriconazole
Abbrevations: ANC = absolute neutrophil count, ARF = acute respiratory failure, BS = breath sounds, CMV = cytomegalovirus, ND = no data, PE = pulmonary embolism, PMN = polymorphonuclear cells (granulocytes), SOB = shortness of breath, WBC = white blood cell count, 10 6 cells/mL. pulmonary fibrosis (2 patients), alpha-1 antitrypsin deficiency (1 patient), and chronic obstructive pulmonary disease (1 patient). The patients with cystic fibrosis had bilateral lung transplants, while the others had single lung transplants (2 patients with left lung transplants and 2 patients with right lung transplants). All 4 patients with single lung transplants had clinical and radiologic evidence of infection in the transplanted lung. Only 1 of 6 patients had acute rejection of their transplants before Fusarium infection. Importantly, 4 of the 6 patients had fungal infections with other organisms before infection with Fusarium. All patients were on a combination of 2 or more immunosuppressive drugs, and 3 of the 6 patients were on antifungal prophylaxis.
Clinical findings included shortness of breath in 4 of the 6 patients, fever in 5 of the 6 patients (range, 36.6-C to 37.9-C), nonproductive cough in 2 of the 6 patients, hemoptysis in 1 of the 6 patients, and headache in 2 of the 6 patients. Clinical examination findings included crackles in 4 of the 6 patients, expiratory wheeze in 1 of the 6 patients, and reduced breath sounds on the affected side in 2 of the 6 patients. Interestingly, there was no sinus involvement in any of the patients. All patients had evidence of infection on chest radiographs and computed tomography (CT) scans.
Laboratory findings included an elevated white blood cell count in 2 of the 6 patients (white cell count range, 4.9Y19.2 Â 10 9 L j1 ) and granulocytosis in 5 of the 6 patients (polymorphonuclear cells range, 75%Y94%). Fusarium was identified in bronchoalveolar lavage (BAL) cultures in 5 of 6 patients, blood cultures in 1 of 6 patients, and sputum cultures in 1 of 6 patients; 2 of 6 patients had septated fungal hyphae recognized by microscopy. Infections were within a year of lung transplantation in 4 of 6 patients, a little over 2 years in 1 patient, and over 15 years in the remaining patient. As noted above, all patients had concomitant infections with various organisms ( Table 2) ; 2 of 6 patients had positive 1Y3 A-D-Glucan (BDG) and galactomannan tests, while 1 of 6 patients had a lone positive galactomannan test ( Table 1 ).
All 6 patients had radiologic investigations including chest radiographs and CT scans. In each case, there was evidence of lung involvement (Figure 1 ). Of the radiologic investigations that were formally reported by a radiologist, the following features were listed: consolidation (1 patient), atelectasis (1 patient), nodular opacities (2 patients), mediastinal lymphadenopathy (1 patient), pleural effusions (2 patients), ground glass opacities (1 patient), and bronchiectasis (2 patients). Note that each patient had some, but not all, of these features.
Liposomal amphotericin B and caspofungin were used to treat 1 of 6 patients, liposomal amphotericin B and voriconazole in 2 of 6 patients, amphotericin B and voriconazole in 1 of 6 patients, and voriconazole alone in 1 of 6 patients. One patient did not receive treatment for fusariosis. The patient treated with amphotericin B and voriconazole was the sole survivor and was alive more than a year after infection; the other 5 patients all succumbed to the infection.
Outcome
Reason 
Literature Review
We identified 3 patients with Fusarium infection following a lung transplant reported in the English-language literature for which adequate clinical data were available. 9, 35, 41 The mean age of infection was 44.3 years (range, 18Y62 yr) ( Table 3 ). The reasons for lung transplantation included advanced bullous emphysema in 1 patient, emphysema due to alpha-1 antitrypsin deficiency and tobacco use in 1 patient, and cystic fibrosis in the remaining patient. The patient with cystic fibrosis had a double lung transplant, while the other 2 patients had a single right lung transplant. All 3 patients were on a combination of 3 immunosuppressive agents when they developed Fusarium infections: prednisolone, azathioprine, and cyclosporine.
Clinical findings included shortness of breath in 1 of 3 patients, fever in 2 of 3 patients, productive cough in 2 of 3 patients, pleuritic chest pain in 1 of 3 patients, asthenia in 1 of 3 patients, and weight loss in 1 of 3 patients. There were no signs of sinus involvement in these patients. All 3 patients had evidence of infection on chest radiographs and CT scans.
Laboratory findings included normal white cell counts in all 3 patients. Fusarium was identified on BAL cultures in 2 of 3 patients, sputum cultures in 1 of 3 patients, and blood cultures in 1 of 3 patients. All 3 patients developed fusariosis soon after lung transplantation. Two of the 3 patients were infected with F. solani, while the other patient was infected with F. proliferatum. MIC data were available for 2 of 3 patients ( Table 4 ). Both of these isolates were resistant to fluconazole and susceptible to amphotericin B.
Amphotericin B was used to treat 1 of the 3 patients, liposomal amphotericin B in 1 of the 3 patients, and posaconazole in 1 of the 3 patients. The patient treated with liposomal amphotericin B died, while the others survived.
DISCUSSION
Fusarium organisms are filamentous fungi found in the soil and air worldwide, especially in tropical and temperate regions. 71, 130 They are mainly plant pathogens but occasionally cause severe infection in farm animals. 28, 71, 75 Fusarium causes a wide range of disease in humans including superficial, locally invasive, and disseminated infections and allergic disease; fusarial mycotoxins have been linked to food poisoning, pancytopenia, and esophageal cancer. 71, 74, 75, 107, 129 Although many species of Fusarium exist, most of the clinical isolates belong to 3 groups: the Fusarium solani species complex (FSSC), the Fusarium oxysporum species complex, and the Gibberella fujikuroi species complex. Isolates from the FSSC are responsible for a majority of the Fusarium mycoses, and at least 20 phylogenetically distinct species of the FSSC have been isolated from clinical specimens. 81 Clinical isolates of FSSC members are phylogenetically similar to isolates from other environmental sources, suggesting that human infections are the result of a susceptible host contacting the FSSC isolate in the environment. 131 F. oxysporum isolates are the second most common cause of Fusarium infections, and a single clonal widespread lineage is responsible for most F. oxysporum infections. 82 Several members from the G. fujikuroi species complex are able to infect humans, most notably F. verticillioides (F. moniliforme) and F. proliferatum. 79 Disseminated infections usually occur only in patients with severe and persistent neutropenia. 75 Clinicians are increasingly aware of Fusarium as an important pathogen of immunocompromised patients associated with high mortality. 15, 29, 74 Of note, Fusarium species and Aspergillus species are often confused because they have similar histologic appearances with septate branching hyphae and they can cause similar clinical syndromes. 38, 115 Some patients are consequently started on amphotericin B, an agent used to treat aspergillosis but with little activity against some Fusarium species. 5, 6, 49, 81, 97, 122 It is, therefore, important to make the correct diagnosis to optimize treatment and improve prognosis. 29 
Epidemiology and Clinical Spectrum
The clinical manifestation of fusariosis depends on the patient_s immune status and the source of the infection. In immunocompetent hosts, there is a broad spectrum of infection ranging from keratitis with contact lens use, peritonitis in patients with intraabdominal catheters, to sinusitis, pneumonia, thromboplebhitis, endophthamitis, fungemia, septic arthritis, and osteomyelitis. 14, 26, 30, 46, 47, 52, 58, 70, 74, 75, 92, 99, 105, 114 Immunocompromised patients with prolonged and extreme neutropenia and severe T-cell immunodeficiency, such as lung transplant patients, are those most at risk of developing fusariosis. 15 They develop similar infections to those in immunocompetent patients but generally have more locally invasive or disseminated fusarial infections. 74, 75 The main site of entry for Fusarium species in lung transplant patients is the airways by inhalation of fusarial conidia followed by areas of skin and mucosal membrane breakdown. 75 Fusarium is ubiquitous in the environment and fusarial conidia have been detected in outdoor air samples. 7, 15, 66 One study 18 found Fusarium to be more prevalent in air samples than Aspergillus. Fusarium species have also been isolated from indoor water storage systems and outdoor water bodies. Water-related activities, such as showering and outdoor water sports, can aerosolize fusarial conidia, thereby making them airborne and facilitating transmission through the airways. 75, 82 The lungs are involved in the majority of cases of disseminated fusariosis in lung transplant patients. 75 Even after controlling for immune status, lung involvement is associated with a higher mortality. 76 Lung lesions in fusarial pneumonia include nodular and cavitary lesions and nonspecific alveolar or interstitial infiltrates. 76 The clinical picture is usually nonspecific, with shortness of breath, nonproductive cough, and pleuritic chest pain. 75, 76 Our results conform with those reported above in the literature. In the current case series, 2 patients had disseminated fusariosis with positive blood cultures, and both these patients had lung involvement with positive BAL samples. Furthermore, all 9 lung transplant patients studied had proven lung involvement with positive BAL samples or sputum cultures and radiologic evidence of infection. There was a high mortality rate (67%) for this group of patients.
Lung transplant recipients are at high risk for other molds that are clinically, histopathologically, and radiologically very similar to fusariosis. This group of patients is susceptible to infection with Aspergillus species and other molds such as Zygomycetes, Scedosporium, and dematiaceous molds. 67, 108, 109 We will briefly touch on 2 of the most common mold infections, Aspergillus and Zygomycetes, but these have been covered elsewhere in more detail. 22, 43, 72, 85, 87, 100 The incidence of invasive Aspergillus infections in lung transplant patients is between 6% and 16% with a high mortality rate. 22, 108, 109 The risk factors for developing aspergillosis are largely the same as those listed above for developing fusariosis, and the clinical presentation of aspergillosis is similar to that of fusariosis with the exception of skin lesions and myalgia occurring more commonly in fusariosis. 22 Furthermore, the radiologic features of aspergillosis are similar to those of fusariosis, with subpeural nodular opacities and cavitation. 22 Lung transplant patients can develop Aspergillus infections anytime from months to years after the lung transplant, but the majority of cases are diagnosed within 6 months of the transplantation. 67, 109 The most common non-Aspergillus molds that colonize airways in lung transplant recipients include Cladosporium, Phialemonium, and Zygomycetes. 108 Zygomycetes are ubiquitous filamentous fungi that can also cause life-threatening infection in lung transplant patients. 22, 100 Risk factors for zygomycosis includes immunosuppression, malignancy, diabetes mellitus, injection drug use, prematurity, receiving deferoxamine therapy, and long-term prophylaxis with voriconazole. 22, 100, 108 Pulmonary disease is most common in immunocompromised patients, and the most common causative organisms include, from most common to least common, Rhizopus species, Mucor species, and Cunninghamella bertholletiae, among others. 22, 100 Common symptoms include fever, dyspnea, chest pain, rhinocerebral infection, and multiorgan failure. 113 Like fusariosis, radiologic features include subpleural lung nodules. 113 
Diagnosis
Diagnosis of fusariosis usually depends on both the clinical and laboratory findings. The following criteria can be used to discern true infection in lung transplant patients: 1) isolation of several colonies of Fusarium from the same specimen or isolation of the same fungus from different specimens; 2) positive identification of the fungus on direct visualization of laboratory samples; and 3) isolation of Fusarium from a site that is more likely to indicate infection than not. 75 (For example, Fusarium identified in a sputum sample from a healthy immunocompetent patient may be the result of recent inhalation of conidia; however, Fusarium isolated from a BAL culture from an immunosuppressed transplant patient should be considered diagnostic of infection, and antifungal therapy initiated.)
Blood cultures are frequently positive in fusariosis, unlike aspergillosis, because Fusarium species sporulate, which facilitates bloodborne dissemination and growth. 56, 75 Confirmation of fusariosis may require histopathology, polymerase chain reaction (PCR), or mass spectrometry. A significant problem with histopathologic diagnosis is that biopsy specimens are sometimes hard to obtain, especially in patients who are critically ill. Furthermore, morphologic discrimination between Fusarium and Aspergillus is highly subjective and difficult because their hyphae appear very similar on direct visualization. Finding hyphae and spores in tissue samples from lung transplant patients is highly suggestive of fusariosis. Distinguishing Fusarium from other fungi may also require in situ hybridization in paraffinembedded tissue specimens. 38, 75 In the current study, only 2 of the 6 patients had positive fungal stains on microscopy with septate hyphae.
Culture methods typically have a low sensitivity for identifying Fusarium, although the fungus can be identified by its microscopic appearance. 48 Species identification may be difficult and may require the use of molecular techniques, and fortunately, PCR-based methods are now available to identify Fusarium species from culture media, blood, and tissue. 39, 44 The detection of Fusarium from blood cultures, however, has poor sensitivity, and species identification is complex and requires a great deal of time and expertise. 40, 75, 128 Furthermore, using the TEF1> gene as a target for species identification remains questionable in some Fusarium species. 62 Some traditional PCR assays use the internal transcribed spacer (ITS) region between the 18S rDNA and 28S rDNA, which has high specificity for certain Fusarium strains such as F. proliferatum, and a combination of several other conserved sequenced regions as the current best molecular method to identify Fusarium isolates to the species level. 107 Molecular markers of fungal infection, such as BDG and galactomannan, can also be used to help diagnose infection. BDG is a nonspecific marker of fungal infection that is usually positive in invasive fusariosis. However, this assay cannot distinguish between Fusarium and other fungi. 78, 84 A positive BDG test and a negative galactomannan test in a lung transplant patient with a mold infection is highly suggestive of Fusarium infection. 75 In the current study, 2 patients had a positive BDG test and a negative galactomannan test, while another patient had a lone positive galactomannan test (defined as a test result of 90.5). 10, 88 Khan et al 48 evaluated the diagnostic usefulness of a BDG test and DNA detection using a highly sensitive and specific nested PCR method on serum and BAL specimens from mice infected with F. oxysporum. They found that the BDG and PCR The use of mass spectrometry to identify clinical isolates of Fusarium has recently gained popularity. Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) is a tool that has been used to characterize fungi. 19, 55, 121, 126 At the moment, though, there is no standard protocol or validated database to use as a benchmark. 62 A major advantage of mass spectrometry is that fungal identification can be completed in 1 hour compared to culture-based methods, which require serial subcultures and microscopic examination of morphologic characteristics that usually take over a week to yield results. PCR-based methods take a minimum of 2 days to yield results. Other advantages to using MALDI-TOF analysis are that each run can include many species and strains of fungi, the results are very consistent, and it is cost efficient. 62, 107 
Treatment
The increase in the incidence of severe fusarial infections and the rapid progression of disease demands early and aggressive treatment of patients with disseminated and invasive infections. 115 The management of fusariosis includes conservative medical and surgical measures. Conservative measures include removal of indwelling lines and central venous catheters in patients with confirmed catheter-related fungemia, while surgical measures include debulking of necrotic and infected tissue in locally invasive disease. 15, 57, 75, 123 In addition, adjunctive therapies exist and can be used to optimize management of these patients. 60, 75, 93, 101 There are currently inconsistent and conflicting recommendations in the literature with regards to the treatment of fusariosis. In the current study, monotherapy with voriconazole, amphotericin B, liposomal amphotericin B, and posaconazole, or dual combination therapy with liposomal amphotericin B and caspofungin, liposomal amphotericin B and voriconazole, and amphotericin B and voriconazole were used for treatment. Mortality was high in this group of patients (67%), and of those who survived, 1 patient was treated with a combination of amphotericin B and voriconazole, 1 patient with amphotericin B, and 1 patient with posaconazole. In general, however, voriconazole is the recommended first-line treatment, with amphotericin B, its lipid formulation, and posaconazole as possible alternatives. 2, 60, 75, 102 The echinocandins (for example, caspofungin, micafungin, anidulafungin) are avoided because Fusarium species have intrinsic re-sistance to the echinocandins. 8, 25 In a study of 273 patients with refractory invasive fungal infections caused by Candida species, Aspergillus species, Fusarium species, Scedosporium species, Cryptococcus neoformans, and Penicillium species, and 28 patients requiring primary treatment of their fungal infections, treatment with voriconazole was associated with a good response in 50% of patients and 45.5% (5 of 11 patients) of patients with fusariosis. 8, 91 Voriconazole was well tolerated as G10% of the patients required a reduction in dose or removal from voriconazole therapy. Voriconazole is approved by the United States Food and Drug Administration for salvage therapy, and posaconazole can also be used as salvage therapy for refractory invasive fusarial infections. 8, 60, 95, 111 Should either of these newer generation triazoles be chosen for Fusarium treatment, they require therapeutic drug monitoring. Variability in plasma drug levels are associated with drug interactions, patient age, nonlinear pharmacokinetics, polymorphisms of the cytochrome P450 CYP2C19 gene, and variable enteral absorption of drugs. 60 A plasma concentration of voriconazole below 1 mg/L is likely to be subtherapeutic, and above 5 mg/L there is neurologic toxicity. 86 The therapeutic levels of voriconazole are not, however, well defined, and a clinical response should be taken into account. The MIC of voriconazole for Fusarium species varies widely and is between 0.25Y8 mg/L. 8 Therefore, the initial target level for voriconazole should be between 1 and 5 mg/L watching for a clinical response. If there is no clinical response, the levels should be increased up to 8 mg/L while monitoring for side effects. If there are side effects or if there is no clinical response at 8 mg/L, therapy should be switched to a second-line agent.
Isavuconazole, formerly BAL4815, is a new broad-spectrum triazole antifungal in the late stages of clinical testing. Guinea et al 34 compared the in vitro activity of isavuconazole to that of voriconazole and fluconazole. The MIC 50 for isavuconazole and voriconazole were both 16 mg/L, and the MIC 90 were 16 mg/L and 4 mg/L against Fusarium species, respectively. This shows that isavuconazole and voriconazole have similar but limited activity against the Fusarium species tested.
Naturally, the treatment of fusariosis should depend on the type of infection, the Fusarium isolate, its susceptibility to antifungals, and host-specific factors. However, given the difficulties in laboratory identification, the species of Fusarium is not always known, let alone the antifungal susceptibilities. At present, amphotericin B and its lipid formulation appear to be better than the newer triazoles (voriconazole, posaconazole, ravuconazole, albaconazole) against F. oxysporum and F. solani. 8, 111, 125 O_Donnell et al 81 tested 19 FSSC isolates with 10 antifungals and terbinafine, a synthetic allylamine antifungal, and amphotericin B showed the lowest MICs. Amphoterin B, though, has clinically poor activity and renal toxicity. 103 Ruiz-Cendoya et al 103 studied the interaction between the new triazoles (voriconazole and posaconazole) with amphotericin B in mice infected with F. oxysporum. Monotherapies of each antifungal agent showed very poor efficacy in vivo. There was a poor response to the combination of amphotericin B and voriconazole; however, there was a much better response to the combination of amphotericin B and posaconazole. 103 The poor efficacy of the amphotericin B and voriconazole combination has been reported in clinical studies, although 2 published cases report that this combination of antifungals led to clinical improvements in patients with F. solani infections before the resolution of neutropenia. 42, 75, 101, 102 This combination was tested in mice infected with F. solani and showed only modest treatment efficacy. 102 Posaconazole shows high MICs for Fusarium species in general, but it is better against F. oxysporum than F. solani. 3, 8, 116 One case report described poor efficacy using combination amphotericin B and posaconazole, although the level of posaconazole was subtherapeutic due to the patient_s poor diet. 54 Azor et al 11 studied the susceptibility of F. verticillioides and F. thapsium to antifungals. F. verticillioides commonly causes fusariosis in humans. The results showed that terbinafine was most effective in treating F. verticillioides in vitro. In decreasing order of potency against F. verticillioides, terbinafine was followed by posaconazole, ravuconazole, voriconazole, amphotericin B, ketoconazole, albaconazole, and itraconazole. 11 Again, terbinafine was the most effective drug in vitro in treating F. thapsium. Voriconazole and amphotericin B followed with equal potencies. The other antifungals tested showed no activity again F. thapsium.
The treatment of other molds differs from the treatment of fusariosis in some important ways. Amphotericin B deoxycholate has broad-spectrum activity against Aspergillus species and Zygomycetes. 22, 104 Liposomal amphotericin B has the same spectrum of activity but fewer side effects. Concerning the azoles: fluconazole is not active against molds; itraconazole has good in vitro activity against Aspergillus but not Fusarium or Zygomycetes; voriconazole has good activity against most Aspergillus species but no activity against Zygomycetes; and posaconazole has good in vitro activity against Aspergillus and Zygomycetes. 13, 20, 22, 31, 94, 104 Caspofungin, anidulafungin, and micafungin all have some activity against Aspergillus but are not effective in monotherapy against invasive aspergillosis and have little or no activity against Zygomycetes. 13, 22, 25, 27 In treating lung transplant patients with fusariosis, antifungal therapy should be complemented by reversal of as many underlying predisposing factors as possible. Low neutrophil and macrophages counts are 2 such predisposing factors to Fusarium infection, which can be treated with immunotherapy. 60 Immunotherapy includes growth factors (granulocyte colony-stimulating factor EG-CSF^and granulocyte-macrophage colony-stimulating factor EGM-CSF^) and granulocyte transfusions for neutropenic patients, and gamma interferon and/or GM-CSF for patients with adequate neutrophil counts. 75 There is, however, a lack of clinical data on the role of immune reconstitution in Fusarium infection, and the best treatment strategy remains unclear. Because of the poor prognosis of fusariosis, especially in lung transplant patients with profound and prolonged neutropenia, G-CSF and granulocyte transfusions are often given. 75, 101 Immunotherapy is well tolerated. 93 To our knowledge, there is currently only 1 case report in the literature of successful treatment of invasive fusariosis with a combination of pharmacologic treatment and immunotherapy. 75, 101 The response to treatment in lung transplant patients can be assessed by 1) disappearance of fevers and other clinical signs of infection, 2) resolution of fungemia, and 3) attenuation of radiologic features of the disease. 75 Note that radiologic features of infection may persist making, their interpretation difficult. Positron emission tomography (PET) and indium-labeled white blood cell scintigraphy can be used to detect inflammation if necessary. 12, 61, 75 
Prognosis
The prognosis of fusariosis in lung transplant patients is directly related to the immune status of the patient, with high mortality rates in patients with prolonged and profound neutropenia. Multivariate predictors of poor outcome include persistent neutropenia, recent corticosteroid therapy, disseminated disease, and lung involvement. Those with no risk factors or whose only risk factor is corticosteroid therapy have statistically significant higher survival rates. 75Y77 In the current study, all 9 lung transplant patients had some predictors of a poor outcome listed above. The mortality rate in this patient group was high (67%), which was consistent with trends published in the scientific literature.
Prevention
Given the poor prognosis of fusariosis and the limited susceptibility to antifungals, prevention of infection is better than the cure. Precautions should be taken to prevent lung transplant patients from coming in contact with known sources of Fusarium. 75 Decreasing the level of immunosuppression should be attempted where possible, especially in patients with a prior history of fusariosis. In addition, active infections, such as skin lesions, should be treated before commencing immunosuppressive therapy. 74, 75 Antifungal prophylaxis should be based on local or organism-specific patterns of susceptibility. Prophylactic antifungals reduce mortality and the incidence of fungal infections in lung transplant patients. 32, 45 Yet there is no standardized approach to antifungal prophylaxis. Husain et al 45 surveyed 50 lung transplant centers worldwide, where roughly 63% of all lung transplants are carried out. They found that aerosolized amphotericin B deoxycholate alone or in combination with itraconazole was the most common prophylaxis strategy used with good results. Itraconazole itself has poor in vitro activity against Fusarium species. 16, 110 Nevertheless, the use of aerosolized amphotericin B deoxycholate with itraconazole might be a more appropriate approach because it has good activity against Aspergillus species, Fusarium species, and Candida species, among others. 2, 23, 60, 63, 89, 90, 98 The drug-drug interactions associated with itraconazole should, however, be taken into account. Other prophylactic strategies used with some success to prevent fungal infections in general include single drug dosing with liposomal amphotericin B, fluconazole, voriconazole, posaconazole, and oral nystatin. 24, 60, 98, 118 Limitations to antifungal prophylaxis include selection of resistance, drug toxicity and interactions to the patient, high cost, and interference with some diagnostic assays. 45 
Conclusions
The Fusarium species is an important but relatively uncommon pathogen of immunocompromised lung transplant patients associated with a high mortality rate. Fusarium species that infect lung transplant patients most frequently are F. solani, F. oxysporum, F. verticillioides, and F. proliferatum. The principle portal of entry for Fusarium species is the airways, followed by the sites of skin breakdown and possibly mucosal membranes. The presentation of fusariosis depends on the immune status of the host and the portal of entry. In humans, Fusarium causes a wide range of disease including superficial, locally invasive, and disseminated infections and allergic disease, and its toxins are associated with food poisoning, pancytopenia, and esophageal cancer. In the lungs, the Fusarium organism causes a nonspecific illness with shortness of breath, nonproductive cough, and pleuritic chest pain. Laboratory confirmation of fusariosis is based on fungal cultures, microscopy, BDG test, galactomannan test, and PCR. Laboratory diagnosis would benefit greatly from MALDI-TOF mass spectrometry, which is a versatile, reliable, and cost-effective assay. Treatment should ideally be based on the Fusarium isolate, susceptibility testing, and host-specific factors. The current recommendations for treating fusariosis empirically in lung transplant patients are voriconazole, amphotericin B, or liposomal amphotericin B firstline and posaconazole for refractory disease. The echinocandins are avoided in treatment. The prognosis of fusariosis is directly related to the immune status of the patient, with high mortality rates in patients with severe and persistent neutropenia. Given the poor outcome of fusariosis, preventing infection is one of the cornerstones of management.
